PlainPharmaWatch

CMS Open Payments · Program Year 2024

Metacel Pharmaceuticals LLC

Metacel Pharmaceuticals LLC reported $1,738.82 across General Payments, Research, and Ownership to 92 physicians and teaching hospitals across 92 transactions.

See the rankings → How this is sourced
$1.7K
All-tracks total
92
Transactions
92
Recipients
−$1.3K
General Payments vs PY2023

Metacel Pharmaceuticals LLC reported $1,738.82 across all CMS Open Payments tracks (General + Research + Ownership) to 92 physicians and teaching hospitals in Program Year 2024 - ranking #1808 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,738.82, averaging $18.90 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer metacel-pharmaceuticals-llc Metacel Pharmaceuticals LLC

$1.7K · #1808/1,925 · 0.0% industry · PY2024

  • TOT $1.7K
  • RANK #1808
  • SHARE 0.0%
  • TXN 92
  • RCP 92
  • CAT 1
  • GEN $1.7K
  • ΔGEN −$1.3K
  • TOP1 2.4%
  • PY 2024

Volume peers

Nearest volume peer: Clinical Laserthermia Systems Americas Inc. ($1.7K)

Arthrosurface Incorporated$1.8KMetacel Pharmaceuticals LLC …$1.7KClinical Laserthermia System…$1.7KStrategic Dentistry LLC$1.7KVital Orthopedics Llc$1.7K
All-tracks payment totals near Metacel Pharmaceuticals LLC (CMS Open Payments PY2024)

Metacel Pharmaceuticals LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Metacel Pharmaceuticals LLC's CMS-reported General Payments decreased by $1.3K (−42.8%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: METACEL PHARMACEUTICALS LLCPY2023: METACEL PHARMACEUTICALS LLCPY2024: Metacel Pharmaceuticals LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$3.0KPY2024$1.7K
PY2023
$3,038.72
PY2024
$1,738.82

What the Data Shows for Metacel Pharmaceuticals LLC

Averaging $18.90 per transaction and $18.90 per recipient, Metacel Pharmaceuticals LLC's Program Year 2024 total comes to $1,738.82 across 92 transactions and 92 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1808 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

92 transactions worth $1.7K make "Food and Beverage" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 1 types of general payments, Metacel Pharmaceuticals LLC's largest category was "Food and Beverage" at $1.7K - 100.0% of General Payments.

How Metacel Pharmaceuticals LLC divides its payments

Ranked by total dollars reported per category

1. Food and Beverage$1.7K
Payment Type Amount Transactions
Food and Beverage $1.7K 92

Recipient Concentration in General Payments

The five largest recipient relationships account for $163.50 (9.4%) of $1,738.82 in this company's General Payments records across 91 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Metacel Pharmaceuticals LLC

The five named recipients with the highest reported General Payments from this company

Ehab M Kodsi$41.53Jacob Thomas Bolz$33.29Brian Kimkyone Gaw$30.36Sunitha Lena Nune$29.16Joshua David Loeb$29.16
  1. 1

    Ehab M Kodsi

    $41.53 across 2 reported transactions

  2. 2

    Jacob Thomas Bolz

    $33.29 across 1 reported transactions

  3. 3

    Brian Kimkyone Gaw

    $30.36 across 1 reported transactions

  4. 4

    Sunitha Lena Nune

    $29.16 across 1 reported transactions

  5. 5

    Joshua David Loeb

    $29.16 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Metacel Pharmaceuticals LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Metacel Pharmaceuticals LLC.

Foundation Medical, Llc

HHI 123

Immunitybio, Inc.

HHI 122

Geistlich Pharma, North America, Inc.

HHI 122

Esperion Therapeutics, Inc.

HHI 121

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Metacel Pharmaceuticals LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Metacel Pharmaceuticals LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.